Search Results - "Azim, H."

ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4) by Paluch-Shimon, S., Cardoso, F., Partridge, A.H., Abulkhair, O., Azim, H.A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K.A., Harbeck, N., Merschdorf, J., Poortmans, P., Pruneri, G., Senkus, E., Spanic, T., Stearns, V., Wengström, Y., Peccatori, F., Pagani, O.

“…The 4th International Consensus Conference for Breast Cancer in Young Women (BCY4) took place in October 2018, in Lugano, Switzerland, organized by the…”
Get full text

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Peccatori, F A, Azim, Jr, H A, Orecchia, R, Hoekstra, H J, Pavlidis, N, Kesic, V, Pentheroudakis, G

Get full text

Long-term toxic effects of adjuvant chemotherapy in breast cancer by Azim, H.A., de Azambuja, E., Colozza, M., Bines, J., Piccart, M.J.

“…Breast cancer is the most common malignant tumor affecting women. Adjuvant systemic therapies have been shown to have a significant impact on reducing the risk…”
Get full text

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients by Lambertini, M., Goldrat, O., Ferreira, A.R., Dechene, J., Azim Jr, H.A., Desir, J., Delbaere, A., t’Kint de Roodenbeke, M.-D., de Azambuja, E., Ignatiadis, M., Demeestere, I.

“…Preclinical evidence suggests a possible negative impact of deleterious BRCA mutations on female fertility. However, limited and rather conflicting clinical…”
Get full text

Green Synthesis of Zinc Oxide Nanoparticles Using Aqueous Extract of Deverra tortuosa and their Cytotoxic Activities by Selim, Yasser A., Azb, Maha A., Ragab, Islam, H. M. Abd El-Azim, Mohamed

“…In recent years, there is a growing interest towards the green synthesis of metal nanoparticles, particularly from plants; however, yet no published study on…”
Get full text

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies by Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F.A., Azim, H.A., Ugolini, D., Pronzato, P., Loibl, S., Moore, H.C.F., Partridge, A.H., Bruzzi, P., Del Mastro, L.

“…The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature…”
Get full text

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5) by Paluch-Shimon, S., Cardoso, F., Partridge, A.H., Abulkhair, O., Azim, H.A., Bianchi-Micheli, G., Cardoso, M.J., Curigliano, G., Gelmon, K.A., Gentilini, O., Harbeck, N., Kaufman, B., Kim, S.B., Liu, Q., Merschdorf, J., Poortmans, P., Pruneri, G., Senkus, E., Sirohi, B., Spanic, T., Sulosaari, V., Peccatori, F., Pagani, O.

“…We dedicate this manuscript in memory of a dear friend and colleague Bella Kaufman. The fifth International Consensus Symposium for Breast Cancer in Young…”
Get full text

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement by Azim, H.A., Michiels, S., Zagouri, F., Delaloge, S., Filipits, M., Namer, M., Neven, P., Symmans, W.F., Thompson, A., André, F., Loi, S., Swanton, C.

“…We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment…”
Get full text

ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) by Loibl, S., Azim, H.A., Bachelot, T., Berveiller, P., Bosch, A., Cardonick, E., Denkert, C., Halaska, M.J., Hoeltzenbein, M., Johansson, A.L.V., Maggen, C., Markert, U.R., Peccatori, F., Poortmans, P., Saloustros, E., Saura, C., Schmid, P., Stamatakis, E., van den Heuvel-Eibrink, M., van Gerwen, M., Vandecaveye, V., Pentheroudakis, G., Curigliano, G., Amant, F.

“…The management of breast cancer during pregnancy (PrBC) is a relatively rare indication and an area where no or little evidence is available since randomized…”
Get full text

Application of ATONA Amplifiers to the Measurement of Uranium Isotopic Ratios by Thermal Ionization Mass Spectrometry by Reinhard, Andrew A., Inglis, Jeremy D., Singleton, Michael J., Kara, Azim H., Steiner, Robert E., LaMont, Stephen P.

“…Uranium isotopic composition can provide valuable information about the history and provenance of a nuclear material; therefore, uranium isotopic analyses are…”
Get full text

Ecofriendly synthesis of pyrano[2,3‐d]pyrimidine derivatives and related heterocycles with anti‐inflammatory activities by AbdEl‐Azim, Mohamed H. M., Aziz, Maged A., Mouneir, Samar M., EL‐Farargy, Ahmed F., Shehab, Wesam S.

“…A versatile, efficient, clean, and facile method was used for the synthesis of pyrano[2,3‐d]pyrimidine derivatives by the one‐pot three‐component condensation…”
Get full text

Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer? by Azim, H.A.

Get full text

In someone else's shoes, are all wearers the same? Empathy in multi-ethnic Asian medical students by Liew, Siaw-Cheok, Fadil Azim, Darlina H.

“…هناك اهتمام كبير للتأكد من النمط الفعلي لاكتساب مهارات التعاطف ولكن هذا الجانب لا يزال غير مستكشف إلى حد كبير في طلاب الطب الآسيويين. استكشفت هذه الدراسة سمة…”
Get full text

Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis by Arecco, L., Blondeaux, E., Bruzzone, M., Latocca, M.M., Mariamidze, E., Begijanashvili, S., Sokolovic, E., Gentile, G., Scavone, G., Ottonello, S., Boutros, A., Vaz-Luis, I., Saura, C., Anderson, R.A., Demeestere, I., Azim, H.A., de Azambuja, E., Peccatori, F.A., Del Mastro, L., Partridge, A.H., Lambertini, M.

“…Despite increasing evidence on the safety of pregnancy after anticancer treatments in breast cancer survivors, many physicians and patients remain concerned…”
Get full text

Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial by Criscitiello, C., Azim, H.A., Agbor-tarh, D., de Azambuja, E., Piccart, M., Baselga, J., Eidtmann, H., Di Cosimo, S., Bradbury, I., Rubio, I.T.

“…The NeoALTTO trial showed that dual HER2 blockade nearly doubles the rate of pathologic complete response (pCR) in patients with primary HER2-positive breast…”
Get full text

Conventional and Microwave‐Activated the Synthesis of a Novel Series of Imidazoles, Pyrimidines, and Thiazoles Candidates by Selim, Yasser, Abd El‐Azim, Mohamed H. M.

“…A novel series of imidazoles, pyrimidines, and thiazoles were synthesized using microwave irradiation and conventional method from commercial available…”
Get full text

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial by Huober, J, Fasching, P.A, Barsoum, M, Petruzelka, L, Wallwiener, D, Thomssen, C, Reimer, T, Paepke, S, Azim, H.A, Ragosch, V, Kubista, E, Baumgärtner, A.K, Beckmann, M.W, May, C, Nimmrich, I, Harbeck, N

“…Abstract The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor…”
Get full text

The current use and attitudes towards tumor genome sequencing in breast cancer by Gingras, I., Sonnenblick, A., de Azambuja, E., Paesmans, M., Delaloge, S., Aftimos, Philippe, Piccart, M. J., Sotiriou, C., Ignatiadis, M., Azim, H. A.

“…There is increasing availability of technologies that can interrogate the genomic landscape of an individual tumor; however, their impact on daily practice…”
Get full text

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO by Di Cosimo, S., Campbell, C., Azim, H.A., Galli, G., Bregni, G., Curigliano, G., Criscitiello, C., Izquierdo, M., de la Pena, L., Fumagalli, D., Fein, L., Vinholes, J., Ng, W.M.J., Colleoni, M., Ferro, A., Naume, B.J., Patel, A., Huober, J., Piccart-Gebhart, M.J., Baselga, J., de Azambuja, E.

“…To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial…”
Get full text

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients by Fouad, T.M., de Azambuja, E., Azim, H.A.

“…In the era of extended endocrine therapy, the interpretation of the results of adjuvant trials is challenging and must take into account the possibility that…”
Get full text